---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-025898"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:09:10.068480+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kintara CFO resigns; CEO Hoffman takes interim CFO role; expects VAL-083 data by Q4 2023

## Summary
- Scott Praill resigned as CFO effective May 31, 2023; will consult for 2 months at $5,000/month.
- CEO Robert Hoffman appointed interim CFO (retaining CEO/Chairman roles), effective June 1, 2023.
- Hoffman voluntarily reduced base salary by $60,000 indefinitely; granted 59,800 RSUs vesting June 1, 2024.
- Company expects results of GBM AGILE study for VAL-083 before end of Q4 2023.
- Expense reductions extend projected cash runway through anticipated data readout date.

## SEC filing metadata
- accession: 0000950170-23-025898
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/0000950170-23-025898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/ktra-20230530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-025898
- JSON: https://secwatch.observer/filing/0000950170-23-025898.json
- Plain text: https://secwatch.observer/filing/0000950170-23-025898.txt

## Key facts
- Executive change
  Scott Praill resigned as Chief Financial Officer at TuHURA Biosciences, Inc./NV.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 30, 2023, Scott Praill resigned from his position as Chief Financial Officer of Kintara Therapeutics, Inc. (the “Company”), effective May 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/0000950170-23-025898-index.htm
- Executive change
  Robert E. Hoffman was appointed as interim Chief Financial Officer at TuHURA Biosciences, Inc./NV.
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Robert E. Hoffman, the current President, Chief Executive Officer, and Chairman of the Board of the Company, to succeed Mr. Praill as the Company’s interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/0000950170-23-025898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.